Paul G. Richardson

TL;DR: A significant unmet need remains for novel agents to treat patients with multiple myeloma and this review focuses on clinical development of panobinostat, with particular emphasis on pharmacokinetics and adverse event management.

TL;DR: This work presents a patient with MM with recurrent cardiotoxicity only when exposed to combination PI and IMiD‐based therapy, and proposes a potential algorithm for cardiot toxicity prevention in this population.

TL;DR: PANORAMA 2 seeks to determine whether panobinostat can sensitize resistant patients to a bortezomib-containing therapeutic regimen, and overall response (≥ partial response [PR), as defined by the European Group of Blood and Marrow Transplantation 1998 criteria.

TL;DR: The primary objectives of the study are to determine the maximum tolerated dose (MTD) and characterize the pharmacokinetic (PK) and pharmacodynamic (PD) marker effects of IPI-504 and the planning of further clinical exploration of IPi-504 including combination with agents such as bortezomib that have proven synergistic in animal models of MM.

TL;DR: The most common post-vaccination adverse event was upper respiratory tract infection (18/137 patients); no rash attributed to vaccine strains or other adverse outcomes potentially related to the vaccines were identified.